Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: Data from two randomized phase III trials

Annals of Oncology

Volumn 26, Issue 4, 2015, Pages 743-749

  Van Soest, Robert J ^a   Templeton, A J ^b,c   Vera Badillo, F E ^b   Mercier, F ^d   Sonpavde, G ^e   Amir, E ^b   Tombal, B ^f   Rosenthal, M ^g   Eisenberger, M A ^h   Tannock, I F ^b   DeWit, R ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^d STAT PROCESS   (France)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^g ROYAL MELBOURNE HOSPITAL   (Australia)

^h JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Androgen deprivation therapy; Docetaxel; Metastatic castration resistant prostate cancer; Neutrophil to lymphocyte ratio

Indexed keywords

AFLIBERCEPT; ALKALINE PHOSPHATASE; DOCETAXEL; HEMOGLOBIN; MITOXANTRONE; PLACEBO; PREDNISONE; ANTINEOPLASTIC AGENT; TAXOID;

AGE DISTRIBUTION; ALKALINE PHOSPHATASE BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; HEMOGLOBIN BLOOD LEVEL; HUMAN; KARNOFSKY PERFORMANCE STATUS; METASTASIS POTENTIAL; MULTICENTER STUDY (TOPIC); NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PAIN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK REDUCTION; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; VALIDATION PROCESS; ADENOCARCINOMA; ADULT; AGED; BONE NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; INTERNATIONAL COOPERATION; LYMPHOCYTE; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEUTROPHIL; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RANDOMIZED CONTROLLED TRIAL; SECONDARY; SURVIVAL RATE; TUMOR INVASION; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL AGENCIES; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEUTROPHILS; PREDNISONE; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL RATE; TAXOIDS;

EID: 84926511984     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu569     Document Type: Article

References (16)

1. Sridhar SS, Freedland SJ, Gleave ME et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment. Eur Urol 2014; 65: 289-299.
2. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
3. Tannock IF, Fizazi K, Ivanov S et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol 2013; 14: 760-768.
4. Ryan CJ, Smith MR, de Bono JS et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368: 138-148.
5. Beer TM, Armstrong AJ, Rathkopf DE et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371: 424-433.
6. Templeton AJ, McNamara MG, Seruga B et al. Prognostic role of neutrophil-tolymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014; 106: dju124.
7. Templeton AJ, Pezaro C, Omlin A et al. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer 2014; 120: 3346-3352.
8. Nuhn P, Vaghasia AM, Goyal J et al. Association of pretreatment neutrophil-tolymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel. BJU Int 2014; 114: E11-E17.
9. Leibowitz-Amit R, Templeton AJ, Omlin A et al. Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castrationresistant prostate cancer. Ann Oncol 2014; 25: 657-662.
10. Proctor MJ, McMillan DC, Morrison DS et al. A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer 2012; 107: 695-699.
11. Halabi S, Lin CY, Small EJ et al. Prognostic model predicting metastatic castrationresistant prostate cancer survival in men treated with second-line chemotherapy. J Natl Cancer Inst 2013; 105: 1729-1737.
12. Chi KN, San Kheoh T, Ryan CJ et al. A prognostic model for predicting overall survival (OS) in patients ( pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel. J Clin Oncol 2013; 31 (suppl): abstr 5013.
13. Halabi S, Lin CY, Kelly WK et al. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2014; 32: 671-677.
14. Brandau S, Dumitru CA, Lang S. Protumor and antitumor functions of neutrophil granulocytes. Semin Immunopathol 2013; 35: 163-176.
15. Gooden MJM, de Bock GH, Leffers N et al. The prognostic influence of tumourinfiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 2011; 105: 93-103.
16. Angelergues A, Maillet D, Flechon A et al. Duration of response to androgendeprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2014; 32 (suppl 4): abstr 282.